AR123700A1 - Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 - Google Patents
Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2Info
- Publication number
- AR123700A1 AR123700A1 ARP210102766A ARP210102766A AR123700A1 AR 123700 A1 AR123700 A1 AR 123700A1 AR P210102766 A ARP210102766 A AR P210102766A AR P210102766 A ARP210102766 A AR P210102766A AR 123700 A1 AR123700 A1 AR 123700A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- independently selected
- substituted
- unsubstituted
- cycloalkyl
- Prior art date
Links
- 102100035762 Diacylglycerol O-acyltransferase 2 Human genes 0.000 title 1
- 101710167503 Diacylglycerol O-acyltransferase 2 Proteins 0.000 title 1
- MYONAGGJKCJOBT-UHFFFAOYSA-N benzimidazol-2-one Chemical class C1=CC=CC2=NC(=O)N=C21 MYONAGGJKCJOBT-UHFFFAOYSA-N 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- 229910052736 halogen Inorganic materials 0.000 abstract 9
- 125000005842 heteroatom Chemical group 0.000 abstract 9
- 229910052760 oxygen Inorganic materials 0.000 abstract 9
- 229910052717 sulfur Inorganic materials 0.000 abstract 9
- 125000000217 alkyl group Chemical group 0.000 abstract 7
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 7
- 150000002367 halogens Chemical class 0.000 abstract 7
- 150000001875 compounds Chemical class 0.000 abstract 6
- 125000001072 heteroaryl group Chemical group 0.000 abstract 6
- 125000000623 heterocyclic group Chemical group 0.000 abstract 6
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 4
- 125000006570 (C5-C6) heteroaryl group Chemical group 0.000 abstract 4
- 125000004093 cyano group Chemical group *C#N 0.000 abstract 4
- 229910052739 hydrogen Inorganic materials 0.000 abstract 4
- 239000001257 hydrogen Substances 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 3
- 125000000171 (C1-C6) haloalkyl group Chemical group 0.000 abstract 3
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 3
- 125000001188 haloalkyl group Chemical group 0.000 abstract 3
- 125000003545 alkoxy group Chemical group 0.000 abstract 2
- 125000003118 aryl group Chemical group 0.000 abstract 2
- 201000010099 disease Diseases 0.000 abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 229910052757 nitrogen Inorganic materials 0.000 abstract 2
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 abstract 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 abstract 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 abstract 1
- 201000001320 Atherosclerosis Diseases 0.000 abstract 1
- 206010007558 Cardiac failure chronic Diseases 0.000 abstract 1
- 229940127194 DGAT2 inhibitor Drugs 0.000 abstract 1
- 206010012289 Dementia Diseases 0.000 abstract 1
- 206010016654 Fibrosis Diseases 0.000 abstract 1
- 206010019708 Hepatic steatosis Diseases 0.000 abstract 1
- 208000035150 Hypercholesterolemia Diseases 0.000 abstract 1
- 208000031226 Hyperlipidaemia Diseases 0.000 abstract 1
- 208000008589 Obesity Diseases 0.000 abstract 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 abstract 1
- 125000005213 alkyl heteroaryl group Chemical group 0.000 abstract 1
- 125000002618 bicyclic heterocycle group Chemical group 0.000 abstract 1
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 208000020832 chronic kidney disease Diseases 0.000 abstract 1
- 230000006999 cognitive decline Effects 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000004761 fibrosis Effects 0.000 abstract 1
- 150000002431 hydrogen Chemical class 0.000 abstract 1
- 125000002768 hydroxyalkyl group Chemical group 0.000 abstract 1
- 125000002950 monocyclic group Chemical group 0.000 abstract 1
- 125000004433 nitrogen atom Chemical group N* 0.000 abstract 1
- 235000020824 obesity Nutrition 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
- C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
- C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
- C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
- C07D235/26—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Neurology (AREA)
- Heart & Thoracic Surgery (AREA)
- Neurosurgery (AREA)
- Hospice & Palliative Care (AREA)
- Biomedical Technology (AREA)
- Gastroenterology & Hepatology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Epidemiology (AREA)
- Urology & Nephrology (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
Se inventan compuestos de fórmula [1] y sales farmacéuticamente aceptables, ésteres y profármacos de los mismos, que son inhibidores de DGAT2. También se proporcionan métodos de preparación de compuestos de fórmula [1], composiciones farmacéuticas que comprenden compuestos de fórmula [1] y métodos de uso de estos compuestos para tratar la esteatosis hepática, esteatohepatitis no alcohólica (EHNA), fibrosis, diabetes mellitus de tipo 2, obesidad, hiperlipidemia, hipercolesterolemia, ateroesclerosis, declive cognitivo, demencia, enfermedades cardiorrenales tales como enfermedades renales crónicas e insuficiencia cardíaca y enfermedades y afecciones relacionadas, que comprenden administrar un compuesto de fórmula [1] a un paciente que lo necesita. Reivindicación 1: Un compuesto de fórmula [1], o una sal farmacéuticamente aceptable del mismo en donde: X, Y y Z se seleccionan independientemente entre N o C(R⁵); R¹ es (1) fenilo sin sustituir o sustituido con 1, 2 ó 3 R⁶, o (2) heteroarilo de 5 ó 6 miembros que contiene 1, 2, 3 ó 4 heteroátomos seleccionados independientemente entre N, O y S, en donde el heteroarilo está sin sustituir o sustituido con 1, 2 ó 3 R⁶, o (3) heteroarilo condensado de 8 a 10 miembros que contiene 1, 2, 3 heteroátomos seleccionados independientemente entre N, O y S, en donde el heteroarilo está sin sustituir o sustituido con 1, 2 ó 3 R⁶; R² es (1) fenilo sin sustituir o sustituido con 1, 2 ó 3 R⁷, (2) heteroarilo de 5 ó 6 miembros que contiene 1, 2 ó 3 heteroátomos seleccionados independientemente entre N, O y S, en donde el heteroarilo está sin sustituir o sustituido con 1, 2 ó 3 R⁷, (3) alquilo C₁₋₆ sin sustituir u opcionalmente monosustituido o disustituido con halógeno, OH, CF₃ o CN, (4) cicloalquilo (C₃₋₆) sin sustituir u opcionalmente monosustituido o disustituido con alquilo C₁₋₃, halógeno, OH, CF₃ o -CN, (5) -alquil (C₃₋₆)C(O)NH₂, (6) heterociclilo de 4 a 6 miembros que contiene 1 ó 2 heteroátomos seleccionados independientemente entre N, O y S en donde el heterociclilo está sin sustituir o sustituido con 1, 2 ó 3 R⁷, (7) -CH₂-arilo sin sustituir o sustituido con 1, 2 ó 3 R⁷, (8) -SO₂alquilo (C₁₋₆) sin sustituir o sustituido con 1, 2 ó 3 R⁷, o (9) -SO₂-arilo sin sustituir o sustituido con 1, 2 ó 3 R⁷; R³ es (1) heterociclilo de 4 a 7 miembros que contiene 1, 2 ó 3 heteroátomos seleccionados independientemente entre N, O y S, (2) heteroarilo de 5 ó 6 miembros que contiene 1, 2 ó 3 heteroátomos seleccionados independientemente entre N, O y S, (3) -alquil (C₁₋₆)-heteroarilo, en donde el heteroarilo es un heteroarilo de 5 ó 6 miembros que contiene 1, 2 ó 3 heteroátomos seleccionados independientemente entre N, O y S, (4) -alquil(C₁₋₆)-arilo, (5) -alquil (C₁₋₆)-heterociclilo, en donde el heterociclilo es un anillo de 3 a 6 miembros que contiene 1 ó 2 heteroátomos seleccionados independientemente entre N, O y S, (6) -alquilo (C₁₋₆), (7) -cicloalquilo (C₃₋₆), (8) -hidroxialquilo (C₁₋₆), (9) -alquil (C₁₋₆)-S(O)₂-NR⁸ᵃR⁸ᵇ, (10) -alquil (C₁₋₆)-S(O)₂-alquilo (C₁₋₃), en donde cada arilo, arilo condensado, heteroarilo, cicloalquilo o heterociclilo está sin sustituir o sustituido con 1, 2 ó 3 R⁹, y en donde cada alquilo está sin sustituir o sustituido con 1, 2 ó 3 R¹⁰; R⁴ es (1) hidrógeno, (2) alquilo (C₁₋₃), o R³ y R⁴ se combinan junto con el átomo de nitrógeno al que están unidos para formar un anillo heterociclilo mono- o bicíclico que contiene 1 ó 2 heteroátomos seleccionados independientemente entre N, O y S, en donde el anillo heterociclilo está sin sustituir o sustituido con 1, 2 ó 3 R¹¹; cuando está presente, cada R⁵ se selecciona entre (1) hidrógeno, (2) alquilo (C₁₋₆), (3) cicloalquilo (C₃₋₆), (4) haloalquilo (C₁₋₆), (5) ciano, (6) halógeno; cuando está presente, cada R⁶ se selecciona independientemente entre (1) ciano, (2) halógeno, (3) -O-alquilo C₁₋₆, (4) cicloalquilo (C₃₋₆), opcionalmente sustituido con halógeno, alquilo C₁₋₃, haloalquilo C₁₋₆ u OH, (5) -C(=O)NH₂, (6) -O-cicloalquilo (C₃₋₆) en donde el cicloalquilo está opcionalmente sustituido con halógeno, alquilo C₁₋₃ u OH, (7) hidroxi, (8) N(R¹¹)₂, (9) haloalquil (C₁₋₆)-, (10) -O-haloalquil (C₁₋₆)-, (11) -SO₂alquilo (C₁₋₆), (12) -SO₂NHalquilo (C₁₋₆), (14) -S-alquilo C₁₋₆, (15) N(R¹¹)C(O)R¹¹, (16) -S-haloalquilo C₁₋₆, o (17) alquilo (C₁₋₆); cuando está presente, cada R⁷ se selecciona independientemente entre (1) alquilo (C₁₋₃), (2) halógeno, (3) alcoxi (C₁₋₆)-, (4) haloalquil (C₁₋₆)-, o (5) hidroxi; cuando están presentes, R⁸ᵃ y R⁸ᵇ se seleccionan independientemente entre (1) hidrógeno, (2) alquilo (C₁₋₃), o (3) cicloalquilo (C₃₋₇); cuando está presente, cada R⁹ se selecciona independientemente entre (1) alquilo (C₁₋₃), (2) haloalquil (C₁₋₃)-, (3) oxo, (4) cicloalquilo (C₃₋₆), (5) N(R¹¹)₂, (6) hidroxi, (7) alcoxil (C₁₋₃)-, (8) ciano, o (9) halógeno; cuando está presente, R¹⁰ se selecciona independientemente entre (1) alcoxi (C₁₋₃)-, (2) hidroxi, (3) halógeno, (4) haloalquil (C₁₋₃)-, o (5) N(R¹¹)₂; R¹¹, cuando está presente, es independientemente (1) hidrógeno, o (2) alquilo (C₁₋₃).
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089068P | 2020-10-08 | 2020-10-08 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR123700A1 true AR123700A1 (es) | 2023-01-04 |
Family
ID=78500729
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210102766A AR123700A1 (es) | 2020-10-08 | 2021-10-06 | Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US11976061B2 (es) |
| EP (1) | EP4225739A1 (es) |
| JP (1) | JP2023545741A (es) |
| KR (1) | KR20230084258A (es) |
| CN (1) | CN116685577A (es) |
| AR (1) | AR123700A1 (es) |
| AU (1) | AU2021356589A1 (es) |
| CA (1) | CA3195014A1 (es) |
| CL (1) | CL2023000997A1 (es) |
| CO (1) | CO2023004365A2 (es) |
| CR (1) | CR20230159A (es) |
| DO (1) | DOP2023000069A (es) |
| EC (1) | ECSP23033936A (es) |
| IL (1) | IL301791A (es) |
| MX (1) | MX2023003842A (es) |
| PE (1) | PE20240216A1 (es) |
| TW (1) | TW202229243A (es) |
| WO (1) | WO2022076495A1 (es) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20240254114A1 (en) | 2022-12-02 | 2024-08-01 | Merck Sharp & Dohme Llc | Preparation of fused azole derivatives as novel diacylglyceride 0-acyltransferase 2 inhibitors |
Family Cites Families (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US162818A (en) | 1875-05-04 | Improvement in brick-kilns | ||
| AU6691798A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel indole and azaindole inhibitors of fructose-1,6-bisphosphatase |
| AU6452098A (en) | 1997-03-07 | 1998-09-22 | Metabasis Therapeutics, Inc. | Novel purine inhibitors of fructose-1,6-bisphosphatase |
| DE69819311T2 (de) | 1997-03-07 | 2004-07-29 | Metabasis Therapeutics Inc., San Diego | Neue benzimidazol inhibitoren der fructose-1,6-bisphosphatase |
| HUP0103143A3 (en) | 1998-09-09 | 2003-01-28 | Metabasis Therapeutics Inc San | Novel heteroaromatic inhibitors of fructose 1,6-bisphosphatase, process for their preparation and their use |
| US20030170691A1 (en) | 2001-12-19 | 2003-09-11 | Millennium Pharmaceuticals, Inc. | Human diacylglycerol acyltransferase 2 (DGAT2) family members and uses therefor |
| AR040241A1 (es) | 2002-06-10 | 2005-03-23 | Merck & Co Inc | Inhibidores de la 11-beta-hidroxiesteroide deshidrogrenasa 1 para el tratamiento de la diabetes obesidad y dislipidemia |
| WO2009000087A1 (en) | 2007-06-28 | 2008-12-31 | Merck Frosst Canada Ltd. | Substituted fused pyrimidines as antagonists of gpr105 activity |
| KR101404781B1 (ko) | 2007-06-28 | 2014-06-12 | 가부시키가이샤 한도오따이 에네루기 켄큐쇼 | 반도체 장치의 제조 방법 |
| WO2009042053A2 (en) | 2007-09-21 | 2009-04-02 | Merck & Co., Inc. | Neuromedin u receptor agonists and uses thereof |
| MD20140103A2 (ro) | 2012-04-06 | 2015-01-31 | Pfizer Inc. | Inhibitori ai diacilglicerol aciltransferazei 2 |
| AR098394A1 (es) | 2013-11-25 | 2016-05-26 | Lilly Co Eli | Inhibidores de dgat2 (diacilglicerol o-aciltransferasa 2) |
| HUE039446T2 (hu) | 2014-03-17 | 2018-12-28 | Pfizer | Diacilglicerol-aciltranszferáz-2 inhibitorok metabolikus rendellenességek és kapcsolódó rendellenességek kezelésében történõ alkalmazásra |
| WO2016036638A1 (en) | 2014-09-05 | 2016-03-10 | Merck Sharp & Dohme Corp. | Isoquinoline derivatives useful as inhibitors of diacylglyceride o-acyltransferase 2 |
| US10568876B2 (en) | 2014-09-05 | 2020-02-25 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| US9877957B2 (en) | 2014-09-05 | 2018-01-30 | Merck Sharp & Dohme Corp. | Tetrahydroisoquinoline derivatives useful as inhibitors of diacylglyceride O-acyltransferase 2 |
| AU2016294347B2 (en) | 2015-07-10 | 2022-07-28 | Ionis Pharmaceuticals, Inc. | Modulators of diacyglycerol acyltransferase 2 (DGAT2) |
| AR109179A1 (es) | 2016-08-19 | 2018-11-07 | Pfizer | Inhibidores de diacilglicerol aciltransferasa 2 |
| MA46856A (fr) | 2016-11-18 | 2019-09-25 | Merck Sharp & Dohme | Dérivés d'indazole utiles en tant qu'inhibiteurs de la diacylglycéride o-acyltransférase 2 |
| MX2019005679A (es) | 2016-11-18 | 2019-08-14 | Merck Sharp & Dohme | Derivados de indol de utilidad como inhibidores de diacilglicerido o-aciltransferasa 2. |
| TWI771766B (zh) | 2019-10-04 | 2022-07-21 | 美商輝瑞股份有限公司 | 二醯基甘油醯基轉移酶２ 抑制劑 |
-
2021
- 2021-10-06 MX MX2023003842A patent/MX2023003842A/es unknown
- 2021-10-06 WO PCT/US2021/053680 patent/WO2022076495A1/en active Application Filing
- 2021-10-06 IL IL301791A patent/IL301791A/en unknown
- 2021-10-06 JP JP2023521375A patent/JP2023545741A/ja active Pending
- 2021-10-06 EP EP21802077.4A patent/EP4225739A1/en active Pending
- 2021-10-06 KR KR1020237015525A patent/KR20230084258A/ko unknown
- 2021-10-06 CR CR20230159A patent/CR20230159A/es unknown
- 2021-10-06 CA CA3195014A patent/CA3195014A1/en active Pending
- 2021-10-06 CN CN202180082235.8A patent/CN116685577A/zh active Pending
- 2021-10-06 PE PE2023001361A patent/PE20240216A1/es unknown
- 2021-10-06 AR ARP210102766A patent/AR123700A1/es unknown
- 2021-10-06 US US17/494,906 patent/US11976061B2/en active Active
- 2021-10-06 AU AU2021356589A patent/AU2021356589A1/en active Pending
- 2021-10-06 TW TW110137150A patent/TW202229243A/zh unknown
-
2023
- 2023-04-05 CO CONC2023/0004365A patent/CO2023004365A2/es unknown
- 2023-04-05 DO DO2023000069A patent/DOP2023000069A/es unknown
- 2023-04-05 CL CL2023000997A patent/CL2023000997A1/es unknown
- 2023-05-08 EC ECSENADI202333936A patent/ECSP23033936A/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| US20220112182A1 (en) | 2022-04-14 |
| DOP2023000069A (es) | 2023-05-15 |
| IL301791A (en) | 2023-05-01 |
| CA3195014A1 (en) | 2022-04-14 |
| US11976061B2 (en) | 2024-05-07 |
| ECSP23033936A (es) | 2023-06-30 |
| CO2023004365A2 (es) | 2023-04-17 |
| CR20230159A (es) | 2023-06-02 |
| CN116685577A (zh) | 2023-09-01 |
| KR20230084258A (ko) | 2023-06-12 |
| PE20240216A1 (es) | 2024-02-16 |
| CL2023000997A1 (es) | 2023-10-06 |
| MX2023003842A (es) | 2023-04-14 |
| WO2022076495A1 (en) | 2022-04-14 |
| JP2023545741A (ja) | 2023-10-31 |
| EP4225739A1 (en) | 2023-08-16 |
| AU2021356589A1 (en) | 2023-05-25 |
| TW202229243A (zh) | 2022-08-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ES2666870T3 (es) | Derivado de dispiropirrolidina | |
| AR118374A1 (es) | Inhibidores de la proteína tirosina fosfatasa y métodos para usarlos | |
| AR115993A2 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR087127A1 (es) | Compuestos que se unen a fxr (nr1h4) y modulan su actividad | |
| AR125425A1 (es) | Inhibidores de proteina tirosina fosfatasa y sus metodos de uso | |
| AR091654A1 (es) | COMPUESTOS QUE CONTIENEN BIARILO COMO AGONISTAS INVERSOS DE RECEPTORES ROR-g | |
| AR035626A1 (es) | Compuestos de indol inhibidores de tirosina quinasa, composicion farmaceutica, procedimiento para prepararla,y, uso de los compuestos en la preparación de medicamentos | |
| AR122593A1 (es) | Compuestos de dihidroquinolinsulfonamida de ciclopropilo | |
| AR046297A1 (es) | Inhibidores de la dpp - iv metodos para prepararlos y composiciones farmaceuticas que los contienen como agente activo | |
| AR089143A1 (es) | Triazolopiridinas sustituidas con actividad inhibidora de ttk | |
| AR088061A1 (es) | Compuestos de pirazol-4-il-heterociclil-carboxamida y metodos de uso | |
| AR122092A1 (es) | Inhibidores de diacilglicerol o-aciltransferasa 2 | |
| PE20231311A1 (es) | Inhibidores de gcn2 y perk quinasas y metodos de uso de los mismos | |
| AR083872A1 (es) | Derivados de acido carbamoil-cicloalquil-acetico sustituidos como inhibidores de nep | |
| AR123848A1 (es) | Compuestos espiro heterocíclicos y métodos de uso | |
| AR123701A1 (es) | Preparación de derivados de oxindol como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| AR111808A1 (es) | Derivados de pirimidina como moduladores del receptor de pge2 | |
| AR123700A1 (es) | Preparación de derivados de benzoimidazolona como nuevos inhibidores de la diacilglicerol o-aciltransferasa 2 | |
| AR124303A1 (es) | Inhibidores de irak4 | |
| AR123648A1 (es) | Compuestos de carbamoilpiridona tricíclicos puenteados y sus usos | |
| AR126612A1 (es) | Compuestos de heteroarilo para el tratamiento de la enfermedad de huntington | |
| ECSP11011196A (es) | Derivados de piperidina | |
| AR123884A1 (es) | Compuestos moduladores del cftr, composiciones y usos de estos | |
| AR120169A1 (es) | Derivados de 2-azaespiro[3.4]octano como agonistas de m4 |